The BioGateway looks to create a borderless life science network to incentivise the growth and acceleration of scientific innovation. With our strong network of UK and European life science partners, the BioGateway provides a platform to promote wider collaboration and partnership.

“BioGateway acts as a conduit for European partnerships between the UK and European life science networks.”

Representing more than a 150 biotechnology companies, academic institutions, disease foundations and other organisations involved in healthcare and life sciences. Our network of member organisations provides the ideal environment to create success and sustainability within a competitive science market.

The BioGateway leverages its network of innovative companies and industry thought leaders to advance policy and promote education, while providing member programs, events, industry information and powers resource efficiency.

Mission Statements
  • Building a borderless life science ecosystem
  • Attracting/developing and rewarding the best science talent
  • Incentivising collaboration to promote healthcare innovation and overcome problem areas

Management Team
Dominique Westbrook

Dominique has 20 years’ experience in a drug discovery background with significant experience in Urology, Cardiovascular and Safety Pharmacology. Dominique is now the CEO of Tetrad Discovery. Dominique set up Tetrad Discovery in 2012 after the closure of Pfizer, Sandwich to act as both a CRO for biotechnology companies and also a conduit to developing novel IP to spin out assets.

Scott Miles

Scott is the Life Science Partner for Kreston Reeves, Scott advises clients across the sector from Pharmaceuticals to Biotech’s and medical devices. He has successful helped clients raise finance through grants, interest free loans, equity raises (VC, Crowd funding and EIS angel investment).

Kreston Reeves provide a full service offering to Life Science companies including outsourced finance office, accounts, audit, funding audits, tax, R&D, Patent Box, Share schemes and International Structuring

Melissa Hanna-Brown

Melissa is currently the UK/EU liaise for technology and innovation for Pfizer Global R&D. Melissa has been heavily involved in both academic and industrial life science sectors. Melissa was previously an academic in the department of Pharmacy, Kings College London where she taught Pharmaceutical Chemistry and maintains her academic interest as a visiting professor in the department of chemistry at the university of Warwick. Melissa also has a wealth of experience in public and professional boards and currently sits on the RSC council and is the elected president of the RSC Analytical Division.

Naz Bashir

With over ten years of management experience in licensing, early stage investment strategies and renewable businesses, Naz has had success in driving sales from licensing and investment strategies in the biofuels, biochemical and food sectors.

Naz has held executive roles and raised finance as part of the management team with various companies across sectors. Naz has managed seed funds, achieving value through profitable exits and IPOs. More recently, Naz co-founded Biocadol Limited, a bioethanol company in which he was the Business Development Director and successfully raised an EIS round which led to a corporate investment and M&A .

Simon Westbrook

Simon has a strong track record of innovation and delivery of drug development programmes with 20 years of drug discovery and development experience, including 15 years at Pfizer Sandwich UK. Simon has played pivotal roles in progressing novel, successful projects from conception of idea to delivery of clinical data. Simon is the named inventor on numerous patents, including p75NTR-Fc for the treatment of pain. He was a team member of four programmes that achieved positive readout in proof-of-concept phase II clinical trials, of which he is the co-inventor of three.

Roger Carline

Roger has a long history of profitable and high value business creation, based on the outputs of research activity including start-up creation, C level and non-executive roles in high-tech SMEs, product and service creation in small and large organisations for sectors ranging from electronics, telecoms and aerospace through to food ingredients and agri-tech. This has been complemented by a decade as a successful researcher and varied advisory roles for business, academia and government.


The UK has long been a world leader for innovation in life sciences. We continue to push the boundaries of discovery and innovation as we look to continue to contribute and strengthen the life science field.

We are moving into an exciting period with untold possibilities however this also poses many obstacles and challenges. With the life science landscape changing so drastically it’s important we position ourselves to work collaboratively to minimise and overcome challenges by utilising our resources effectively.

It has become imperative to develop infrastructure which connects academics, industry, investors, clinicians and crucially the NHS to develop, incentivise and adopt ideas to create better patient outcomes.

Cluster theory’ for economic development suggests cluster formations allow life science companies to operate more competitively because of the network and mutual support available in the cluster.

UK Regions

Geographical distribution of medical biotechnology companies.

Image sources: Strength and Opportunity report 2013. Contains Ordinance Survey data. © Crown Copyright and database right (2013).

Distribution of companies, turnover and employment across the UK for the medical biotechology sector


As Kents life science network, The BioGateway represents a unique cluster formation bridging borders between the UK and European science networks providing member companies an opportunity to operate more competitively.

Kent science network represents over a 150 companies employing over 6800 employees working within the life science sector in Kent. Fast evolving into a hub for innovation, Kent plays home for some of the biggest names across life sciences including Pfizer, Mylan, Novartis, Smiths Medical and Aesica to mention but a few. This is no surprise given the world class talent available, the funding opportunities, the dedicated sites and facilities and the ease of access.

Kent has developed a wealth of talent as a leader in drug research and development, diagnostics, drug manufacturing and medical devices. Whilst retaining a high level of talent from industry, Kent also boasts an excellent pool of life science graduate talent from both Kent university and Canterbury Christ Church University.

With two of the leading science parks in the UK, Kent is host to both Discovery Park and Kent Science park amongst various other incubator spaces. Offering state of the art lab spaces to support growth of organisations from start-ups to global leaders.

With the development of the High Speed rail, Kent provides quick and easy access into London access bodies such as NICE, MHRA, The Francis Crick Institute and the Wellcome trust. Kent also provides easy access to other European life science communities with Brussels and Paris both accessible in under 2 hours through the Eurostar.

Kent Science Network continues to grow with the inward investment of companies relocating to Kent with both Genea and Purogenix both relocating recently, looking to recruit heavily creating jobs and business opportunity within Kent.

As Kents life science network, The BioGateway represents a unique cluster formation bridging borders between the UK and European science networks providing member companies an opportunity to operate more competitively.

The Kent Life Science Cluster